MiNK Therapeutics to Announce Q3 2025 Financial Results and Showcase Key Clinical and Corporate Achievements Advancing iNKT Platform Towards Critical Development
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: Nov 05 20250mins
Financial Results Announcement: MiNK Therapeutics will release its Q3 2025 financial results on November 14, 2025, before the market opens, following a presentation at the SITC Annual Meeting showcasing new clinical data for its agenT-797 iNKT cell therapy.
Conference Call Details: A conference call and webcast will be held at 8:30 a.m. ET on the same day to discuss financial results, recent clinical progress, and future corporate milestones, with access information provided for participants.
Company Overview: MiNK Therapeutics is focused on developing allogeneic iNKT cell therapies for cancer and immune disorders, with its lead candidate, agenT-797, currently in clinical trials for various conditions, including solid tumors and graft-versus-host disease.
Forward-Looking Statements: The press release includes forward-looking statements about the potential and development of iNKT-based therapies, highlighting associated risks and uncertainties as outlined in MiNK's SEC filings.
INKT.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on INKT
Wall Street analysts forecast INKT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INKT is 39.00 USD with a low forecast of 35.00 USD and a high forecast of 43.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 12.750
Low
35.00
Averages
39.00
High
43.00
Current: 12.750
Low
35.00
Averages
39.00
High
43.00
H.C. Wainwright
H.C. Wainwright
Neutral -> Buy
upgrade
$35
2025-08-15
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$35
2025-08-15
upgrade
Neutral -> Buy
Reason
H.C. Wainwright upgraded MiNK Therapeutics to Buy from Neutral with an unchanged price target of $35 post the Q2 report. The firm sees the company's Phase 2 gastric cancer data later this year as a "significant catalyst" for the shares. The majority of patients in the Phase 2 gastric study are now enrolled and initial efficacy data is expected in the back half of the year, the analyst tells investors in a research note. H.C. Wainwright points out MiNK shares are now well below its price target.
H.C. Wainwright
Emily Bodnar
Buy
to
Neutral
downgrade
$35
2025-07-15
Reason
H.C. Wainwright
Emily Bodnar
Price Target
$35
2025-07-15
downgrade
Buy
to
Neutral
Reason
H.C. Wainwright analyst Emily Bodnar downgraded MiNK Therapeutics to Neutral from Buy with a $35 price target.
H.C. Wainwright
H.C. Wainwright
Buy -> Neutral
downgrade
$35
2025-07-15
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$35
2025-07-15
downgrade
Buy -> Neutral
Reason
H.C. Wainwright downgraded MiNK Therapeutics to Neutral from Buy with an unchanged price target of $35 after the company announced that a publication discussing the mechanism of action of CAR-iNKT cells was published in Frontiers in Immunology. With the shares up over 400% since last week, the "majority of the enthusiasm has been priced in for the near-term," the analyst tells investors in a research note. As a result, H.C. Wainwright downgraded MiNK on valuation, It looks to additional updates from the agenT-797 Phase 2 gastric trial in the upcoming months to reevaluate the stock's thesis.
William Blair
Matthew Phipps
Outperform -> Market Perform
downgrade
2025-07-14
Reason
William Blair
Matthew Phipps
Price Target
2025-07-14
downgrade
Outperform -> Market Perform
Reason
William Blair analyst Matthew Phipps late Friday downgraded MiNK Therapeutics to Market Perform from Outperform without a price target after the company announced a publication in Nature's Oncogene describing a patient with treatment-refractory testicular cancer treated with Opdivo plus agenT-797 in the Phase I trial achieved a complete remission. In response to the publication, MiNK shares traded up over 700%, and exceeding William Blair's pervious fair value estimate of $33, the analyst tells investors in a research note. As such, the firm downgraded the stock on valuation ahead of additional data from the ongoing gastric cancer trial. MiNK shares in premarket trading are down 27% to $47.00 after rally 730% on Friday to $64.17.
See All Ratings
About INKT
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?